July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA approved subcutaneous isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis US LLC) for multiple myeloma treatment regimens across relapsed, refractory, and newly diagnosed disease settings.
A real-world analysis found that mRNA SARS-CoV-2 vaccination was associated with lower 3-year mortality after CAR T-cell therapy in patients with hematologic malignancies.
SDM visits are a cornerstone of Medicare-covered lung cancer screening—but do you know how they influence whether patients return year after year? Take this brief quiz to test your knowledge!
Trends from the National Cancer Database show that the use of neoadjuvant systemic therapy (NST) has increased sharply over the past decade but not uniformly across cancer types or stages. Test your...
This year we’ve explored critical clinical insights, cutting-edge care strategies, and expert perspectives on our podcast. Today, we’re excited to count down the five standout podcast episodes that...
As researchers continue exploring early-intervention strategies for high-risk smoldering multiple myeloma, understanding the basic pathophysiology of plasma cell disorders (and the targets of emerging...
In this Consultant Case Report Insights, Nandini N. Patel, OMS III, provides an overview of her study, “Metastatic Malignant Melanoma from Unknown Origin to the Jejunum: A Case Report.” In the video...
Author-selected classifications for 2026 submissions highlight the breadth of practical, peer-reviewed, clinical education at Consultant, with dermatological disorders, pediatrics, primary care, cancer, and...
In the latest installment of the Myelofibrosis Caregiver Interview Series, Tim F. from Pittsburgh, PA, talks with Fadi Haddad, MD about the caregiver perspective, highlighting the substantial day-to-day...
Monitoring treatment response in myelofibrosis requires a balanced assessment of patient-reported symptoms, objective scoring tools, hematologic parameters, and spleen size. In part 1 of this Myelofibrosis...
In this video, Brian M. Slomovitz, MD, discusses his recent study demonstrating a significant improvement in disease-free survival with pembrolizumab in patients with dMMR endometrial cancer. He explains...